Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer

References

• HennessyBTColemanRLMarkmanMOvarian cancerLancet20093741371138219793610
   PubMed Web of Science ®Google Scholar
• MarkmanMWalkerJLIntraperitoneal chemotherapy of ovarian cancer: a review with a focus on practical aspects of treatmentJ Clin Oncol20062498899416461779
   PubMed Web of Science ®Google Scholar
• BookmanMABradyMFMcGuireWPEvaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the Gynecologic Cancer IntergroupJ Clin Oncol2009271419142519224846
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMTakahashiFDose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trialLancet20093741331133819767092
   PubMed Web of Science ®Google Scholar
• BurgerRABookmanMAWalkerJLPhase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer: a Gynecologic Oncology Group studyJ Clin Oncol20102818sLBA1
   Web of Science ®Google Scholar
• PerrenTSwartAMPfistererJICON 7: a Phase III Gynecologic Cancer Intergroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer Presentation at ESMO, Milan, Italy2010
   Google Scholar
• VergoteITropeCGAmantFNeoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerN Engl J Med201036394395320818904
   PubMed Web of Science ®Google Scholar
• MarkmanMLiuPYWilczynskiSPhase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trialJ Clin Oncol2003212460246512829663
   PubMed Web of Science ®Google Scholar
• MarkmanMBookmanMSecond-line treatment of ovarian cancerOncologist20006263510706647
   PubMedGoogle Scholar
• MarkmanMViewing ovarian cancer as a “chronic disease”: what exactly does this mean?Gynecol Oncol200610022923016226801
   PubMed Web of Science ®Google Scholar
• PapahadjopoulousDAllenTNGabizonASterically stabilized liposomes: Improvement in pharmacokinetic and antitumor therapeutic efficacyProc Natl Acad Sci U S A19918811460114641763060
   PubMed Web of Science ®Google Scholar
• VaageJDonovanDMayhewETherapy of human ovarian carcinoma xenographs using doxorubicin encapsulated in sterically stabilized liposomesCancer199372367136758252484
   PubMed Web of Science ®Google Scholar
• VaageJBarbert-GuillemEAbraRTissue distribution and therapeutic effects of intravenous free and liposomal doxorubicin against prostatic carcinoma xenographsCancer199473147814848111716
   PubMed Web of Science ®Google Scholar
• HuangSKMayhewEGilaniSPharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinomaCancer Res199252677467811458465
   PubMed Web of Science ®Google Scholar
• UzielyBJeffersSIsacsonRLiposomal doxorubicin (Dox-SL™): antitumor activity and unique toxicities during two complementary Phase I studiesJ Clin Oncol199513177717857602367
   PubMed Web of Science ®Google Scholar
• MuggiaFMHainsworthJDJeffersSPhase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulationJ Clin Oncol1997159879939060537
   PubMed Web of Science ®Google Scholar
• GordonANFleagleJTGuthrieDRecurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecanJ Clin Oncol2001193312332211454878
   PubMed Web of Science ®Google Scholar
• GordonANGranaiCORosePGPhase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancerJ Clin Oncol2000183093310010963637
   PubMed Web of Science ®Google Scholar
• MarkmanMKennedyAWebsterKPhase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneumGynecol Oncol20007836937210985896
   PubMed Web of Science ®Google Scholar
• GordonANTondaMSunSLong-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecol Oncol2004951815385103
   PubMed Web of Science ®Google Scholar
• MuggiaFMBralyPSBradyMFPhase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol20001810611510623700
   PubMed Web of Science ®Google Scholar
• GoreMEFryattIWiltshawETreatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecol Oncol199013383393
   Google Scholar
• O’ByrneKSBlissPGrahamJDA Phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naïve relapsed ovarian cancerProc Am Soc Clin Oncol200221203a
   Google Scholar
• MutchDGOrlandoMGossTRandomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol2007252811281817602086
   PubMed Web of Science ®Google Scholar
• FerrandinaGLudovisiMLorussoDPhase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerJ Clin Oncol20082689089618281662
   PubMed Web of Science ®Google Scholar
• VergoteIFinklerNdel CampoJPhase 3 randomized study of canfosfamide (Telcyda®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerEur J Cancer2009452324233219515553
   PubMed Web of Science ®Google Scholar
• RosePGMaxsonJHFuscoNLiposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosagesGynecol Oncol20018232332811531287
   PubMed Web of Science ®Google Scholar
• CamposSMPensonRTMaysARThe clinical utility of liposomal doxorubicin in recurrent ovarian cancerGynecol Oncol20018120621211330951
   PubMed Web of Science ®Google Scholar
• TanyiJLSmithJARamosLPredisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancerGynecol Oncol200911421922419446868
   PubMed Web of Science ®Google Scholar
• PignataSScambiaGSavareseACarboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin in patients with advanced ovarian cancer: final analysis of the MITO-2 randomized multicenter trialJ Clin Oncol20102818s952a
   Google Scholar
• Pujade-LauraineEWagnerUAavall-LundqvistEPegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapseJ Clin Oncol2010283323332920498395
   PubMed Web of Science ®Google Scholar
• MarkmanMMoonJWilczynskiSSingle agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) Phase 3 randomized trialGynecol Oncol201011632332520044128
   PubMed Web of Science ®Google Scholar
• MonkBJHerzogTJKayeSBTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancerJ Clin Oncol2010283107311420516432
   PubMed Web of Science ®Google Scholar